Affordable Access

deepdyve-link
Publisher Website

Assessment of vision-related quality of life and depression and anxiety rates in patients with neovascular age-related macular degeneration.

Authors
  • Fernández-Vigo, J I1
  • Burgos-Blasco, B2
  • Calvo-González, C2
  • Escobar-Moreno, M J2
  • Shi, H2
  • Jiménez-Santos, M2
  • Valverde-Megías, A2
  • Reche-Frutos, J2
  • López-Guajardo, L2
  • Donate-López, J2
  • 1 Departamento de Oftalmología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria (IdISSC), Madrid, España; Centro Internacional de Oftalmología Avanzada, Madrid, España. Electronic address: [email protected]
  • 2 Departamento de Oftalmología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria (IdISSC), Madrid, España.
Type
Published Article
Journal
Archivos de la Sociedad Espanola de Oftalmologia
Publication Date
Sep 01, 2021
Volume
96
Issue
9
Pages
470–475
Identifiers
DOI: 10.1016/j.oftal.2020.11.010
PMID: 33376027
Source
Medline
Keywords
Language
Spanish
License
Unknown

Abstract

To assess the vision-related quality of life and the depression and anxiety rates in patients with neovascular Age-Related Macular Degeneration (nAMD). A cross-sectional study of patients with nAMD treated with intravitreal injections was performed. The patients completed two validated questionnaires: the Visual Functioning Questionnaire (VFQ-25, score from 0 to 100), and the Hospital Anxiety and Depression Scale (HADS) questionnaire. Age, gender and visual acuity (VA) in the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was registered. Fifty-five patients with nAMD participated with a mean age of 80.9±6.6 years-old (range 67 to 93) and a mean VA in the best eye of 73.5±12.7 letters (range 44 to 95). The global VFQ-25 mean score was 57.4±21.9 being 38.9±13.2 for the general vision and 42.0±19.5 for the general health. VA in the best eye was associated with the global score of the VFQ-25 scale (R=.608; P<.001), but no correlation was observed with general health (P=.936). In the HADS scale, 26.9% and 25.5% of patients had symptoms of depression and anxiety respectively. A negative correlation was found between the HADS and VFQ-25 scales for the general vision score (R=-0.438). This study elucidates the impact of vision impairment and the visual functioning in nAMD, describing an important rate of depression and anxiety symptoms. Copyright © 2020 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.

Report this publication

Statistics

Seen <100 times